Most of the Treg world is built on FoxP3+ regulatory T cells.
These are “the classic immunology textbook variety”. The ones that suppress immune responses to keep the system from attacking itself.
Tr1X is built on a different cell type entirely.
Type 1 regulatory T cells – “Tr1” cells – are induced rather than thymically derived, suppress immune responses primarily through IL-10 (not the contact-dependent mechanisms of FoxP3+ Tregs), and have a different homing pattern in tissue.
To date, Tr1s have note really been given a whole lot of therapeutic attention. Well, Tr1X is bringing data to ASGCT 2026 on two engineered Tr1 cell therapy programs.
The clinical-stage one is TRX103. Allogeneic, off-the-shelf, infused after HLA-mismatched stem cell transplant to prevent graft-versus-host disease.
The release included some early Phase 1 data: no dose-limiting toxicities, 100% engraftment, dose-dependent persistence, induction of a tolerogenic immune environment via IL-10 signaling. No quantitative efficacy numbers in the release – looking forward to something coming out at ASGCT.
To be honest, their preclinical program is more interesting (to me, at least).
TRX319 is a CAR-Tr1 cell. Same engineered Tr1 backbone, except now the cells carry a CD19 CAR. The cells target B cells (like a normal CD19 CAR-T) but instead of killing, they drive immunoregulation through IL-10. Tr1X is positioning it for multiple sclerosis.
The Biotech Voyager
Early-stage biotech signals, personalized.
The signals that matter to you — contextualized and written directly to you — so you cut through the noise and immediately understand why it matters.
Let’s take a look at why I think this approach works particularly well in MS.
If you look at Anti-CD20 antibodies (Ocrevus, Kesimpta), they work in MS by depleting B cells, but they don’t affect the underlying T-cell-driven autoimmunity.
Even CAR-T programs from companies, like Kyverna in myasthenia gravis, can induce deep B-cell depletion (enough to force an “immune reset” among the B cell population)…
But here’s the thing…MS pathology has both B and T cell components.
TRX319 takes a different swing.
It’s not a KILLER…it’s a suppressor.
A suppressor with a homing signal.
It’s a clever idea on paper. Whether it works comes down to two things.
First, whether the Tr1 cells persist long enough to matter. Tr1s historically have shorter lifespans than FoxP3+ Tregs, and CAR engagement may or may not solve that.
Second, whether localized IL-10/TGF-β release at B-cell-dense sites is enough to retrain the broader T-cell pathology of MS, or whether you need to be hitting autoreactive T cells more directly.
Preclinical MS models are notoriously bad predictors of clinical outcomes…EAE has fooled a lot of programs into thinking they had MS drugs.
The competitive context: there’s been a wave of Treg programs lately.
Cellenkos has cord blood-derived Tregs in Phase 2 for aplastic anemia.
Mozart Therapeutics is going after CD8 Tregs in T1D.
Sonoma Biotherapeutics, Quell Therapeutics, GentiBio all have FoxP3+ Treg programs in various stages.
Tr1X is staking out a different cell type and a different targeting strategy.
For now, the milestone to watch is TRX103 efficacy data at ASGCT. If it shows clean GvHD prevention with the safety profile their early data hints at, the platform validates and TRX319 starts to look like a serious MS bet. If TRX103 stumbles, the whole Tr1 thesis takes a hit.
Different cell, different mechanism. Worth seeing if it actually plays out differently in patients.
The Biotech Voyager Podcast
Deep dives on the signals shaping early-stage biotech.
